GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Forward PE Ratio

Gyre Therapeutics (Gyre Therapeutics) Forward PE Ratio : 0.00 (As of May. 29, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Forward PE Ratio?

Gyre Therapeutics's Forward PE Ratio for today is 0.00.

Gyre Therapeutics's PE Ratio without NRI for today is 0.00.

Gyre Therapeutics's PE Ratio for today is 0.00.


Gyre Therapeutics Forward PE Ratio Historical Data

The historical data trend for Gyre Therapeutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Forward PE Ratio Chart

Gyre Therapeutics Annual Data
Trend
Forward PE Ratio

Gyre Therapeutics Semi-Annual Data
Forward PE Ratio

Competitive Comparison of Gyre Therapeutics's Forward PE Ratio

For the Biotechnology subindustry, Gyre Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gyre Therapeutics's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's Forward PE Ratio falls into.



Gyre Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Gyre Therapeutics  (NAS:GYRE) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Gyre Therapeutics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gyre Therapeutics (Gyre Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines